Novartis’s Zolgensma Loses EU Accelerated Assessment

 
• By Alexandra Shimmings

Companies pleased at gaining an EU accelerated assessment for a product should be aware that the agency offers no guarantee that they will get to keep it. Novartis’s Zolgensma is one of seven drugs whose review the EMA has taken off the fast track.

Speed_Bump
Speed restrictions applied in Europe for Zolgensma • Source: Shutterstock

More from New Products

More from Scrip